Blueprint Medicines Corporation

Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally. The company develops AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company develops BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. Blueprint Medicines Corporation was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. The company was incorporated in 2008 and is based in Cambridge, Massachusetts. As of July 18, 2025, Blueprint Medicines Corporation operates as a subsidiary of Sanofi.